Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 2. Growth inhibition of HUVEC and HepG2 cells at different concentration of doxorubicin. Data from 3 independent experiments are shown. *p < 0.05, n.s. not significant, vs 0.02μM.